Splenopentin (1-100 μM) augments human NK cells and has no cytotoxicity[2].
Splenopentin (0.1 ng/mL-10 μg/mL; 3 h) induces phenotypic differentiation of both T- and B-cell precursor cells[3].
Splenopentin (1 mg/kg; i.p. three times a week for 7-90 d) accelerates Langerhans cell recruitment and leads to pretreatment levels of Langerhans cell (LC) density in the skin of mice[4].
Splenopentin (0.01-100 μg per mouse; i.p.) has no demonstrable effect on neuromuscular transmission of mice[3].
References:
[1]. Singh VK, et, al. Thymopentin and splenopentin as immunomodulators. Current status. Immunol Res. 1998;17(3):345-68.
[2]. Rastogi A, et, al. Augmentation of human natural killer cells by splenopentin analogs. FEBS Lett. 1993 Feb 8;317(1-2):93-5.
[3]. Audhya T, et, al. Contrasting biological activities of thymopoietin and splenin, two closely related polypeptide products of thymus and spleen. Proc Natl Acad Sci U S A. 1984 May;81(9):2847-9.
[4]. Gruner S, et, al. Stimulation of the recruitment of epidermal Langerhans cells by splenopentin. Arch Dermatol Res. 1990;281(8):526-9.